This indicates that there is an opportunity for therapeutic intervention by targeting CDO1 in particular cancer contexts in which CDO1 silencing is not occurring as it was described that CDO1 silencing by methylation was occurring preferentially in KEAP1-mutated cases in NSCLC [64]. The gene discussed is KEAP1; the disease is cancer.